Mesa Laboratories, Inc
Mesa Laboratories designs and manufactures life sciences tools and critical quality control solutions used in regulated pharmaceutical, healthcare, and medical device applications. Its portfolio combines consumable products, hardware, and service offerings that help customers verify product integrity, improve safety, and meet regulatory requirements.
Fiscal year 2026 · change from previous year
Development 2021–2026
Business
Share of revenueChemical sterilization indicators, biologics, and process challenge devices used to verify sterilization performance.
Genomics-related products and workflows used in clinical and research settings.
Protein analysis and peptide synthesis equipment, consumables, and support services for biologics development.
Metrology-based products for measuring and calibrating critical parameters in regulated environments.
Products
Reported · share of revenue- Products81.6 %
- Services18.4 %
Source: 10-K FY2026, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
Mesa sells primarily to regulated end markets where product quality, traceability, and compliance are essential. Its customers include pharmaceutical and biopharmaceutical companies, healthcare providers, medical device manufacturers, laboratories, and distributors that serve those end users. Demand is driven by validation, quality control, capital equipment replacement, and recurring consumables and service needs.
Buy protein analysis, peptide synthesis, sterilization control, and quality assurance tools to support regulated development and manufacturing.
Buy calibration, environmental monitoring, and sterilization validation products to meet quality and regulatory standards.
Buy metrology and monitoring solutions used in hospitals, labs, and clinical environments.
Purchase products for resale and local market access, especially outside the U.S.
Buy hardware and consumables for protein analysis and peptide synthesis workflows.
Strategy
Mesa’s strategy combines organic growth, acquisitions, and operating efficiency improvements. Management emphasizes expanding the customer base, adding products, raising volumes, and using price increases where possible, while also integrating acquisitions that broaden the portfolio and global footprint. The company’s operating model is built around high-margin niche markets and a lean system called the Mesa Way.
Expanding the installed base and product mix supports recurring demand and reduces reliance on any single product line.
Acquisitions add products, customers, and geographic reach in adjacent regulated markets.
Lean manufacturing and administrative discipline help preserve margins in niche hardware and service businesses.
Geography
Mesa is a global business with manufacturing operations in the United States and Europe and sales coverage across North America, Europe, and Asia Pacific. In fiscal 2025, about 52% of revenue was earned outside the United States, highlighting meaningful exposure to foreign currency, trade policy, and regional demand cycles. The company also noted product revenues sourced from U.S. subsidiaries and sold into China, which creates tariff sensitivity and cross-border execution risk.
Risks
Mesa faces execution risk from its dependence on regulated end markets, distributors, and global supply chains. Its business is also exposed to tariffs, foreign exchange, acquisition integration, and goodwill/intangible asset impairment, especially in businesses where demand can shift with capital spending cycles. Cybersecurity and data privacy risks matter because the company handles sensitive customer and operational information across a distributed global footprint.
- Tariffs and international trade policyImpact: HighLikelihood: High
Products sourced outside the U.S. and sold into markets such as China may face tariff-driven margin pressure or demand disruption.
Exposure: China and cross-border shipments
- Distributor and channel partner dependenceImpact: HighLikelihood: Medium
A meaningful share of products is sold through distributors that Mesa cannot fully control, so inventory swings or partner weakness can distort results.
Exposure: Global indirect sales channels
- Supply chain and sole-source inputsImpact: HighLikelihood: Medium
Limited-source materials and components can cause production interruptions, delays, and higher costs.
Exposure: Manufacturing operations
- Goodwill and intangible asset impairmentImpact: HighLikelihood: Medium
A large balance of acquired intangibles can be written down if future cash flows or discount rates deteriorate.
Exposure: Clinical Genomics and Peptides reporting unit
- Acquisition integration riskImpact: MediumLikelihood: Medium
Growth depends partly on buying and integrating businesses at acceptable prices and realizing synergies.
Exposure: Portfolio expansion strategy
- Cybersecurity and data privacyImpact: MediumLikelihood: Medium
Operational disruption or data loss could affect shipments, customer trust, and regulatory compliance.
Exposure: Remote workforce and global IT systems
Accounting
Judgemental itemsThe company carries a large balance of acquired intangibles, and weak performance or higher discount rates could trigger write-downs.
Impact: Can materially reduce operating income and net income
Recent acquisitions affect reported revenue, amortization, and comparability across periods.
Impact: Can distort year-over-year growth and margins
Expense depends on estimated forfeitures, performance achievement, and fair value models.
Impact: Affects operating expense and EPS
Deferred tax assets and reserves require management judgment and can change with tax authority outcomes.
Impact: Can move tax expense materially
Hardware, consumables, and service revenues have different timing and cyclicality, and distributor inventory levels can shift reported sales timing.
Impact: Affects quarterly comparability and gross margin
Similar listed companies
Publicly listed companies with a comparable business focus.
Thermo Fisher Scientific Inc
TMO · Measuring & Controlling Devices, NEC
Thermo Fisher Scientific is a U.S.-based life sciences and laboratory company organized around four segments: Life Sciences Solutions, Analytical Instruments,…
Harvard Bioscience, Inc
HBIO · Laboratory Analytical Instruments
Harvard Bioscience designs, manufactures, and sells life-science research tools used in drug discovery, translational medicine, and preclinical testing.
STERIS plc
STE · Orthopedic, Prosthetic & Surgical Appliances & Supplies
STERIS plc provides products and services used to prevent infection and support sterile processing across healthcare and life sciences settings.
Biomerica, Inc
BMRA · In Vitro & In Vivo Diagnostic Substances
Danaher Corporation
DHR · Industrial Instruments For Measurement, Display, and Control
Danaher is a U.S.-based science and technology company organized around biotechnology, life sciences, and diagnostics.
Visa Inc
V · Services-Business Services, NEC
Last updated: 24/09/2026